Drugs / MPC-3100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00920205 | Jun 2009 → Jun 2011 | cancer | Myrexis Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPC-3100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00920205 ↗ |
| Action | Inhibit | “designed to reduce the activity of a protein known as "heat shock protein 90", or "Hsp90"” NCT00920205 ↗ |
| Route | Oral | “oral daily dose for 21 days in a 28-day cycle” NCT00920205 ↗ |